Venezuela’s emerging pharmaceutical markets threatened5 Nov 2017
Economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers.
Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers according to GlobalData, a leading data and analytics company.
The company’s latest report: ‘CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela’, reveals that the country’s total pharmaceutical market value was $12.6 billion in 2015, increasing from $5.7 billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%.
However, Venezuela’s current economic crisis may reverse this healthy growth rate with healthcare services now becoming more expensive in the country.
In 2015, the average price of healthcare services increased by 38.5% from the previous year. Out of pocket expenditure in 2015 was also high at 67.3% and drug prices are now considerably higher than the region average of $7.86. In 2016 the average drug price in Venezuela was $21.95, the highest in the entire Latin America region.
The supply of pharmaceuticals in the country is heavily dependent on imports with the market growing significantly from 2009 to 2012. Since then pharma imports have dipped with pharmacies facing a shortage of essential medicines despite the efforts of the government to maintain supply. As of May 2017, about 85% of the country’s required drug demand was not being met.
Tathagata Ghosh, Healthcare Analyst at GlobalData commented: ‘As well as pharmaceuticals, the medical device market is heavily dependent on imported products. The US is the major supplier for medical devices, although in recent times Cuba, Mexico and Brazil have replaced some US exports. Disposable healthcare items such as syringes, surgical clothes and hospital furniture are all manufactured domestically.’
Inefficient healthcare infrastructure, shortage of medicines in pharmacies and a high level of private healthcare expenditure leave plenty of room for improvement in the healthcare system.
Venezuelan healthcare facilities are mainly limited to primary hospitals, due to a high share of primary care in the overall healthcare provision. The number of secondary and tertiary hospitals is very low. The government provides easy access to primary hospitals through the Misión Barrio Adentro (In the Neighbourhood Mission). Under this program, primary care contents are available in rural and urban areas to provide healthcare services to the whole population.
Tathagata continued: ‘By 2013, Misión Barrio Adentro had saved about 1.7 million lives and is looking to expand further with plans to set up 824 new clinics in co-ordination with local provincial governments.’
Venezuela is ranked 187 out of 190 countries in ease of doing business. In July 2017, the rating firm Standard & Poor’s downgraded Venezuela’s economy to *CCC with a negative outlook. Moody’s also downgraded its rating to **Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook.
Aptar Pharma to showcase an industry first
12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
New SGS biopharmaceutical testing capabilities in Illinois
11 Sep 2018
The new services will focus on quality control analysis and stability testing of biopharmaceuticals.Read more
Exciting skincare to protect against blue light emitted by phones and devices
10 Sep 2018
Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.Read more
24/7 life science manufacturing IT service launches
7 Sep 2018
Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.Read more
Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin
6 Sep 2018
Novel dosage form employs Catalent’s proprietary stick pack dosage form.Read more
Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors
5 Sep 2018
Customers to benefit from simplified, scalable solutions for intensified cell culture.Read more
Boehringer Ingelheim to build new tablet manufacturing facility
4 Sep 2018
Facility to manufacture innovative drugs for worldwide market launches and technologically advanced production.Read more
Plasticell wins military contract to develop regenerative medicines for the battlefield
4 Sep 2018
Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.Read more
Bio processing and manufacturing league table ranks US top and China bottom
3 Sep 2018
US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation